ofatumumab – a valid treatment option for chronic lymphocytic leukemia patients
Clicks: 104
ID: 158237
2017
Salma M AlDallal Haematology Laboratory, Amiri Hospital, Kuwait City, Kuwait Abstract: Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia patients. This article summarizes this antibody’s therapeutic effect on chronic lymphocytic leukemia. Keywords: ofatumumab, cell-mediated cytotoxicity, chronic lymphocytic leukemia
| Reference Key |
sm2017therapeuticsofatumumab
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;AlDallal SM |
| Journal | liver transplantation : official publication of the american association for the study of liver diseases and the international liver transplantation society |
| Year | 2017 |
| DOI | DOI not found |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.